These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 10394022)

  • 1. Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion.
    Berman J; Dietze R
    Chemotherapy; 1999 Jun; 45 Suppl 1():54-66. PubMed ID: 10394022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion).
    Dietze R; Milan EP; Berman JD; Grogl M; Falqueto A; Feitosa TF; Luz KG; Suassuna FA; Marinho LA; Ksionski G
    Clin Infect Dis; 1993 Dec; 17(6):981-6. PubMed ID: 8110956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients.
    Gaeta GB; Maisto A; Di Caprio D; Scalone A; Pasquale G; Felaco FM; Galante D; Gradoni L
    Scand J Infect Dis; 2000; 32(6):675-7. PubMed ID: 11200380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex.
    Sundar S; Murray HW
    J Infect Dis; 1996 Mar; 173(3):762-5. PubMed ID: 8627049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar.
    Maheshwari A; Seth A; Kaur S; Aneja S; Rath B; Basu S; Patel R; Dutta AK
    Pediatr Infect Dis J; 2011 Feb; 30(2):180-1. PubMed ID: 20823781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
    Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
    N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.
    Sundar S; Agrawal G; Rai M; Makharia MK; Murray HW
    BMJ; 2001 Aug; 323(7310):419-22. PubMed ID: 11520836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis.
    Berman JD; Ksionski G; Chapman WL; Waits VB; Hanson WL
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1978-80. PubMed ID: 1416890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
    Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol.
    Khodabandeh M; Rostami A; Borhani K; Gamble HR; Mohammadi M
    Parasitol Int; 2019 Oct; 72():101934. PubMed ID: 31129197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
    Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
    Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.
    Sundar S; Jha TK; Thakur CP; Mishra M; Singh VR; Buffels R
    Am J Trop Med Hyg; 2002 Feb; 66(2):143-6. PubMed ID: 12135284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
    Minodier P; Retornaz K; Horelt A; Garnier JM
    Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis.
    Sundar S; Gupta LB; Rastogi V; Agrawal G; Murray HW
    Trans R Soc Trop Med Hyg; 2000; 94(2):200-4. PubMed ID: 10897369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.